Approaches to hepatitis C treatment and cure using NS5A inhibitors

James J Kohler, Emory University
James H Nettles, Emory University
Franck Amblard, Emory University
Selwyn Hurwitz, Emory University
Leda C. Bassit, Emory University
Richard A Stanton, Emory University
Maryam Ehteshami, Emory University
Raymond F Schinazi, Emory University

Journal Title: Infection and Drug Resistance
Volume: Volume 7
Publisher: Dove Medical Press | 2014, Pages 41-56
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.2147/IDR.S36247
Permanent URL: http://pid.emory.edu/ark:/25593/ft0bg

Final published version:
http://www.dovepress.com/approaches-to-hepatitis-c-treatment-and-cure-using-ns5a-inhibitors-peer-reviewed-article-IDR

Copyright information:
© 2014 Kohler et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), which permits distribution of derivative works, making multiple copies, distribution, public display, and publicly performance, provided the original work is properly cited. This license requires credit be given to copyright holder and/or author, copyright and license notices be kept intact. This license prohibits exercising rights for commercial purposes.

Accessed December 30, 2017 9:28 AM EST
Approaches to hepatitis C treatment and cure using NS5A inhibitors

James J Kohler1,2
James H Nettles1,2
Franck Amblard1,2
Selwyn J Hurwitz1,2
Leda Bassit1,2
Richard A Stanton1
Maryam ehteshami1
Raymond F Schinazi1,2

1Center for AIDS Research and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; 2Atlanta Veterans Affairs Medical Center, Decatur, GA, USA

Abstract: Recent progress in the understanding of hepatitis C virus (HCV) biology and the availability of in vitro models to study its replication have facilitated the development of direct-acting antiviral agents (DAAs) that target specific steps in the viral replication cycle. Currently, there are three major classes of DAA in clinical development: NS3/4A protease inhibitors, NS5B polymerase inhibitors, and NS5A directed inhibitors. Several compounds thought to bind directly with NS5A are now in various clinical trial phases, including the most advanced, daclatasvir (BMS-790052), ledipasvir (GS-5885), and ABT-267. While many NS5A-targeted compounds demonstrate picomolar potency, the exact mechanism(s) of their action is still unclear. In the clinic, NS5A HCV inhibitors show promise as important components in DAA regimens and have multifunctionality. In addition to inhibiting viral replication, they may synergize with other DAAs, possibly by modulating different viral proteins, to help suppress the emergence of resistant viruses. Structure-based models have identified target interaction domains and spatial interactions that explain drug resistance for mutations at specific positions (eg, residues 93 and 31) within NS5A and potential binding partners. This review provides insights into the unique complexity of NS5A as a central platform for multiple viral/host protein interactions, and possible mechanism(s) for the NS5A inhibitors currently undergoing clinical trials that target this nonstructural viral protein.

Keywords: HCV replication complex, direct acting antivirals (DAAs), clinical trials

Introduction

Hepatitis C virus (HCV) is a global health burden, with approximately 170 million people (3% of the world’s population) estimated to be infected worldwide. More than three million people contract HCV each year, and while 15%–30% of all HCV infections clear spontaneously, the remaining 70%–85% (an estimated 120–130 million) of infections will develop into chronic hepatitis, which can lead to steatosis, cirrhosis, and hepatocellular carcinoma. Unfortunately, most are unaware of their infection — HCV-associated liver diseases may only manifest after decades in undiagnosed individuals — and can potentially transmit the virus to others, primarily through contaminated blood. In addition, HCV reinfection after treatment has been reported, making vaccine development desirable. Accordingly, the burden of HCV-associated disease is predicted to rise over the next 20 years. In fact, in the US, HCV has now superseded human immunodeficiency virus type 1 (HIV-1) as the leading cause of mortality due to an infectious agent.

As a member of the Flaviviridae, the general replication cycle of HCV is similar to that of other viruses of this family and replicates entirely within the cytoplasm.
Because it does not establish latency, HCV is curable, although the mechanism by which it mediates persistence remains unclear. Among all recognized positive-strand ribonucleic acid (RNA) viruses, HCV is unique in its ability to establish a chronic infection.9 The HCV genome consists of a 9.6 kb, positive-sense, single-stranded, enveloped RNA, which encodes three structural proteins (core, E1, and E2), the ion channel protein p7, and six nonstructural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B).10 Each of these proteins has a role in HCV entry, infection, replication, or maturation and is therefore a potential drug target.

HCV is highly heterogeneous, which can be an obstacle to the development of a universal treatment and a preventative vaccine. According to the World Health Organization, six major HCV genotypes and several subtypes have been identified throughout the world. Subtypes 1a/b account for approximately 70% of all infections in the US, Europe, China and Japan,11 and the remainder are generally genotype 2, 3, and 4.12 The HCV genotype strongly predicts the response to the currently approved HCV treatments.

Over the last decade, the standard of care comprised a dual-therapy regimen containing peginterferon alpha (PEG-IFN), given once per week as a subcutaneous injection, and ribavirin (RBV), a guanosine (ribonucleic) analog given orally twice daily. Individuals with HCV genotype 1 or 4 infection are less likely (40%–50%) to demonstrate a sustained viral response (SVR) with these treatments compared with individuals with genotype 2 or 3 disease (75%–85%).13,14 In 2011, the first NS3/4A HCV protease inhibitors (PIs), telaprevir and boceprevir, were approved. These direct-acting antiviral agents (DAAs) have now been licensed in several countries for use in combination with PEG-IFN and RBV, for the treatment of genotype 1 subjects. Unfortunately, many infected individuals, regardless of genotype, have been ineligible or unable to tolerate the standard of care regimen due to adverse effects and long treatment durations. Therefore, newer treatments with improved characteristics are needed to address the growing unmet medical needs.

HCV primarily infects liver parenchymal cells (hepatocytes). Because the liver is a highly specialized and complex organ, it is difficult to adequately model its biology in vitro. However, significant efforts have been directed at developing cell culture models to elucidate the viral replication in vitro.15,16 Specifically, the discovery of host cell receptor molecules that potentiate HCV infection has helped to overcome these obstacles, and the development of human hepatoma cell lines (eg, Huh-7 and Hep3B cells) has led to recent advances in the understanding of HCV structure and replication.10,15

There is now a broad pipeline of drugs in clinical development for treatment of HCV that relies on DAAs alone. DAAs block viral production by directly inhibiting one or more steps of the HCV replication cycle and are in various stages of clinical development.13,17–24 DAAs currently include first-generation, second-wave, and second-generation NS3/4A PIs, nucleoside inhibitors and nonnucleoside inhibitors of the NS5B RNA polymerase, and NS5A complex inhibitors.25–28 Highly potent once-a-day, DAA-only combinations are now in Phase II and III of clinical development.20 This review will focus on the unique complexity of NS5A as a drug target, with its putative protein interactions and possible mechanism(s) of action. We will summarize the most recent mechanistic research on drugs targeting NS5A and the ongoing clinical trials with these agents.

### Structure and function of NS5A

NS5A is a 447 amino acid (aa), zinc-binding phosphoprotein comprised of three domains separated by two linker regions (Figure 1).29 Structurally, the amino-terminus of NS5A comprises the amphipathic α-helix, which is responsible for anchoring to the endoplasmic reticulum (ER) and ER-derived membranes, including lipid droplets (LDs).30,31

In one study, the structure encoded in the first 31 aas of HCV genotype 1a domain I (D-I) was determined, by nuclear magnetic resonance spectrometry (NMR), to include an extended amphipathic helix (AH), which oscillates in plane with the cytosolic surfaces of the model membrane bilayers and which is thought to be conserved for all genotypes (Figure 1).32 The remaining subdomains were subsequently crystallized using different truncated sequences of genotype 1b (Figure 1).33,34 Both three-dimensional (3D) structures reveal a novel folded core between aa 36–100 designated as subdomain 1a (D1a), that coordinates a zinc atom via four cysteines, yet the two structures pack into two unique conformations of the homodimer. The remaining residues in D-I (aa 101–213), designated subdomain 1b (D1b), include a putative RNA-binding domain at the dimer interface of one of the structures.35 The structural predictions were recently confirmed by in vitro biochemical assays, where the D-I residues involved in dimerization and RNA binding were identified.35 Domains II (D-II) and III (D-III) of NS5A are intrinsically disordered and are therefore flexible. This may confer NS5A’s promiscuous ability to interact with numerous proteins.36–40 Specifically, D-II is involved with binding to cyclophilin A and, therefore, has the potential to antagonize the innate...
immune response to HCV. D-III seems to be important for the assembly of infectious viral particles.

NS5A exists in two forms (designated p56 and p58), based on electrophoretic mobility. The p56 form is primarily unphosphorylated or is basally phosphorylated by several kinases in different regions, and data suggests that p58 hyperphosphorylation is performed by casein kinase I isoform alpha. More recently, the essential host factor, lipid kinase phosphatidylinositol 4-kinase III alpha (PI4KIIIalpha) has been shown to bind NS5A and regulate its phosphorylation state. Surprisingly, the upregulation of PI4KIIIalpha has been shown to result in lower levels of the hyperphosphorylated p58. While the exact role of NS5A phosphorylation in regulating HCV RNA replication is not completely understood, it may contribute to a switch between viral RNA replication versus RNA translation and/or packaging.

Recent studies suggest that NS5A hyperphosphorylation appears to play different roles between in vitro and in vivo systems, and the degree and requirements for hyperphosphorylation may vary between different HCV genotypes and isolates. While NS5A is essential to HCV genome replication and is required for virion morphogenesis, its specific role in these processes has yet to be determined. What is certain is that HCV, like virtually all plus-strand RNA viruses, has the hallmark feature of forming a membrane-associated replication complex composed of virus proteins, replicating RNA and...
altered cellular membranes. All the HCV NS proteins, including NS5A, interact with host cell membranes, either directly as membrane-binding proteins, or in the case of NS3, via interaction with the membrane-anchoring protein NS4A. The interaction of these viral proteins with the membrane forms tight structures that accumulate as a “membranous web” to house the viral replication complexes.

Even though NS5A has no known enzymatic activity, its interaction with the membranous web is critical for viral replication, and modification/deletion of specific residues of the membrane-binding AH domain impairs both ER localization and RNA replication. NS5A interacts with a myriad of cellular and viral factors, including viral RNA, which likely enables it to perform multiple roles within the virus replication cycle. For example, NS5A is a novel structural class of RNA-binding protein with the ability to bind to HCV RNA, and to bind NS5A directly at the conserved AH residue tryptophan (W) 9.

In short, while the specifics of the NS5A inhibitor mechanism(s) of action are not fully understood, it is likely that NS5A functions as a key modulator of this process.

**NS5A inhibitor mechanism(s) of action**

A recent clinical study of nine HCV-infected persons who were administered 10 or 100 mg single doses of the NS5A inhibitor daclatasvir revealed a multiphasic decline in serum HCV. An initial, rapid two-log, drop in HCV RNA levels over the first 6 hours and a half-life (t_{1/2}) of 48 minutes was observed, suggesting a direct inhibition of virus assembly or the secretion in serum. This was followed by a much slower phase of decline (t_{1/2} = 6–9 hours), which was indicative of an effect on viral RNA synthesis. These clinical findings suggest that NS5A inhibitors have mechanism(s) that affect both viral genome replication and the assembly/release of infectious HCV particles in humans, related to those previously seen in cell-based studies.

In vitro experiments indicate that NS5A is a “promiscuous” protein, interacting with multiple host and virus
components, most likely involved in the membranous web formation.\textsuperscript{53,71} For instance, NS5A has been shown to interact with core protein to enhance the formation of HCV particles\textsuperscript{72–74} and with NS3, NS4A, and NS5B to modulate its phosphorylation, in addition to its role in binding RNA.\textsuperscript{33,56,75–77} However, it is not precisely clear which complex(es) are the target of NS5A-directed inhibitor drugs. Attempts at monitoring inhibition, in a cell-free system with only purified NS5A, have not been successful to date, suggesting that targeting the NS5A complex may require additional host and viral factors. On the other hand, the HCV replicon system has provided a rapid and efficient way to monitor the effects of NS5A inhibitors on HCV RNA production within the membranous web complex. It is noteworthy that the effect(s) of NS5A inhibitors on viral assembly and release cannot be studied directly using the replicon system, as replicon cells do not contain the envelope gene.

Recent mechanistic studies using immunofluorescence to track NS5A localization in replicon-containing cells following treatment with NS5A inhibitors have suggested that these drugs reduce viral RNA production in new, rather than preformed, replication complexes, which may correlate with the observed slow rate of viral load decay seen in clinical trials.\textsuperscript{78,79} These studies also demonstrated that NS5A inhibitors significantly shift the distribution of NS5A from the ER to LDs and that such redistribution is ablated in cells with drug-resistant mutations (eg, Y93H and L31V).\textsuperscript{79} Since NS5A has previously been shown to colocalize with core proteins on LDs,\textsuperscript{31,80} drug binding at the LD stage may interfere with viral assembly and particle release at the cell membrane, thus accounting for the fast decay (as part of the multiphasic decline) seen in the clinic.

Additional mechanisms for the biphasic clinical response to NS5A-targeted inhibitors may include functional complexes with essential host factors, such as PI4KIII\textalpha or TIP47. PI4KIII\textalpha creates a PI4P-rich membranous environment supporting HCV replication as well as modulating NS5A phosphorylation.\textsuperscript{49,81} TIP47 is an LD-binding host protein that has previously been shown to regulate RNA replication via direct interaction with HCV NS5A and to have a key role in the viral assembly/release of the related dengue flavivirus.\textsuperscript{82,83}

While we have described at least two distinct possible modes of action for the drug response observed in infected persons, these modes of action are not likely to be exclusive. If NS5A inhibitors only affect the formation of new viral replication complexes, this mode of action would be limited to a relatively narrow time period in the HCV replication cycle; however, if NS5A inhibitors additionally affect the virus assembly complex, preventing the maturation of viral particles and the spread of infection, these mechanisms would occur at two different stages of the replication cycle and could account for the observed multiphasic kinetics.\textsuperscript{67,68}

Both mechanisms suggest that the ideal NS5A inhibitors should be administered at doses that maintain steady-state trough concentrations (C\textsubscript{trough}) that will maintain an SVR at week 12 (SVR12). Because it is assumed that only the unbound fraction of drug is free to diffuse into hepatocytes, many studies have reported maintenance of C\textsubscript{trough} > the in vitro determined 90% effective concentration (EC\textsubscript{90}) against the targeted strain of HCV, corrected for binding to plasma proteins (protein-corrected potency), as a biomarker of therapeutic efficacy (Table 1). Once-a-day antiviral regimens generally demonstrate a greater degree of compliance. Once-a-day formulations are more easily achieved using drugs that have a long plasma t\textsubscript{1/2} (eg, ledipasvir (t\textsubscript{1/2}=49.7 hours), ABT-267 (t\textsubscript{1/2}=28.1 hours), and daclatasvir (t\textsubscript{1/2}=12.8 hours)). However, given the high potency of NS5A inhibitors, drugs with short t\textsubscript{1/2} may also be considered as once-a-day regimens, provided a sufficiently high dose could be administered to maintain an effective steady-state trough without producing systemic toxicity. The pharmacokinetics of NS5A inhibitors in clinical development are summarized in Table 1.

**Chemical space of NS5A-directed inhibitors**

Daclatasvir was discovered using HCV replicon systems for high throughput screening (HTS), which identified a low micromolar hit that selected mutations in the NS5A coding region.\textsuperscript{84} Further screening of structurally similar compounds identified a low nanomolar lead that selected the same mutations.\textsuperscript{84} Investigation of the mechanism of the lead’s increased potency revealed a homodimeric metabolite to be the active component.\textsuperscript{85} Further medicinal chemistry optimization of the symmetric, dimeric scaffolds resulted in the picomolar-active structure of BMS-790052, also known as daclatasvir.\textsuperscript{85,86} A recent review mapped the chemical space of over 50 compounds from the patent literature. They were found to center around daclatasvir’s chemical structure.\textsuperscript{57} This large set of compounds can be grouped into two general chemotype classes (summarized in Figure 3). The class 1 compounds are dimers presenting a chemical motif of two peptidic caps joined by conjugated aromatic core linkers and include the known clinical compounds daclatasvir (BMS-790052), GSK-2336805, and ledipasvir (65–5885), with the structures shown in Figure 3. The most
Table 1 Pharmacokinetic parameters of NS5A inhibitors

<table>
<thead>
<tr>
<th>NS5A inhibitor</th>
<th>Dose (mg)</th>
<th>Cmax (ng/mL)</th>
<th>Tmax (hr)</th>
<th>AUC per dose (ng·hr/mL)</th>
<th>t1/2 (hr)</th>
<th>Ctrough SS (ng/mL)</th>
<th>PC EC90 (ng/mL)</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT-267</td>
<td>25 QD</td>
<td>56.2 (38)</td>
<td>4.6 (16)</td>
<td>529 (36)</td>
<td>28.1 (22)</td>
<td>31.1**</td>
<td>NA</td>
<td>124,131</td>
</tr>
<tr>
<td>ACH-3102</td>
<td>300 QD</td>
<td>876.4 (28)</td>
<td>6.9 (18)</td>
<td>9,904.5 (31)</td>
<td>111.6 (24)</td>
<td>300</td>
<td>NA</td>
<td>125</td>
</tr>
<tr>
<td>AZD-7295</td>
<td>90 cid</td>
<td>97.9</td>
<td>1.0–1.5</td>
<td>294</td>
<td>4.4**</td>
<td>29.5</td>
<td>NA</td>
<td>114,133</td>
</tr>
<tr>
<td></td>
<td>350 bid</td>
<td>304.4</td>
<td>1.0–1.5</td>
<td>1031</td>
<td>5.2**</td>
<td>145.5</td>
<td>NA</td>
<td>114,133</td>
</tr>
<tr>
<td>BMS-790052</td>
<td>60 QD</td>
<td>1,726 (21)</td>
<td>1 (1–2)</td>
<td>15,120 (35)</td>
<td>12.8 (9.6)</td>
<td>254.6 (42)</td>
<td>Gen 1a, 1b: 0.28</td>
<td>99,126,134</td>
</tr>
<tr>
<td>GS-5816</td>
<td>150 QD</td>
<td>669 (48.1)</td>
<td>2–3</td>
<td>4,890 (45.4)</td>
<td>15.2 (12–15)</td>
<td>63.4 (42.8)</td>
<td>N/A</td>
<td>118</td>
</tr>
<tr>
<td>GS-5885</td>
<td>90 QD</td>
<td>247.7 (45.4)</td>
<td>4–6</td>
<td>1,592.4 (59.5)</td>
<td>49.7 (54.3)</td>
<td>115.9 (42.6)</td>
<td>Gen 1: 0.91</td>
<td>104,127</td>
</tr>
<tr>
<td>GSK-2336805</td>
<td>75 QD</td>
<td>NA</td>
<td>NA</td>
<td>5,500 (90)</td>
<td>7–10</td>
<td>128†</td>
<td>NA</td>
<td>116,132</td>
</tr>
<tr>
<td>IDX-719</td>
<td>50 QD</td>
<td>32.4 (25)</td>
<td>4 (2–4)</td>
<td>387 (30)</td>
<td>23 (17)</td>
<td>8.2 (34)</td>
<td>Gen 1a/b: 2.3/1.7</td>
<td>128,129</td>
</tr>
<tr>
<td>PPI-668</td>
<td>320 QD</td>
<td>1,500–5,000</td>
<td>2</td>
<td>NA</td>
<td>6**</td>
<td>311</td>
<td>NA</td>
<td>117</td>
</tr>
<tr>
<td>MK-8742</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>130</td>
</tr>
</tbody>
</table>

Notes: BMS-790052 = daclatasvir; GS-5885 = ledipasvir; IDX719 = samatasvir. The Cmax, Cmax SS, and terminal t1/2 were reported with %CV or ranges (in parentheses), when available. Clinical doses may not be finalized; some dosages displayed were inferred from early conference presentation or press release. The PC EC90 were calculated using the replicon EC50, molecular weight, and/or serum protein binding. The Cmax was calculated by extrapolation using Cmax and t1/2. The Cmax SS and dose interval (t1/2) = 1/2 trough SS. The Cmax SS and dose interval (t1/2) were calculated using the Cmax, Cmax SS, and dose interval (t1/2). Coadministration of ABT-267 with ritonavir increased the mean Cmax and AUC by 68% and 62%, respectively, and by 88% and 56%, respectively, when administered with food compared with administration under fasting conditions. The dose adjustments of BMS-790052 of 30 mg QD with azatavir (300 mg QD) plus ritonavir (100 mg QD), and of 90 mg QD with efavirenz (600 mg QD) is expected to generate a daclatasvir exposure similar to that for 60 mg of daclatasvir administered alone. GSK-2336805 demonstrated a two- to four-fold greater Cmax and AUC in chronic HCV-infected than in healthy persons. The dose adjustments of BMS-790052 of 30 mg QD with atazanavir (300 mg QD) plus ritonavir (100 mg QD), and of 90 mg QD with efavirenz (600 mg QD) is expected to generate a daclatasvir exposure similar to that for 60 mg of daclatasvir administered alone. GSK-2336805 demonstrated a two- to four-fold greater Cmax and AUC in chronic HCV-infected than in healthy persons. The dose adjustments of BMS-790052 of 30 mg QD with atazanavir (300 mg QD) plus ritonavir (100 mg QD), and of 90 mg QD with efavirenz (600 mg QD) is expected to generate a daclatasvir exposure similar to that for 60 mg of daclatasvir administered alone. The class 2 compounds are diverse chemotypes and include monomers with very different chemical scaffolds. In general, the class 2 compounds are less active than Class 1 in replicon assays with nanomolar, rather than picomolar, median 50% effective concentration (EC50) values. “Compound 4,” with an EC50 of 160 nM, was the most potent, in vitro, of a series built on a piperazine-aryl carbamate motif seen in these three, while the linkers can vary widely. The class 2 compounds are distinct from class 1 and include monomers with very different chemical scaffolds. In general, the class 2 compounds are less active than Class 1 in replicon assays with nanomolar, rather than picomolar, median 50% effective concentration (EC50) values. “Compound 4,” with an EC50 of 160 nM, was the most potent, in vitro, of a series built on a piperazine-aryl scaffold from Merck and Co, Inc (Whitehouse Station, NJ, USA). Mutations selected by this compound localize on NS5A, near the homodimer interface of the crystal structure, suggesting that effecting dimerization may be part of its molecular mechanism. However, some other class 2 members clearly point to alternative mechanism(s) of action for NS5A-targeted compounds. For example, 4-anilino quinazoline (AL-9) from Arrow Therapeutics Limited (London, UK) was first thought to target NS5A, based on selected mutations that emerged in NS5A. However, AL-9 was recently shown to directly inhibit purified PI4KIIIβ and to reduce PI4P levels in the plasma membrane, which are known to regulate viral propagation. Systematic explorations of the structure–activity relationships (SARs) for compounds from both class 1 and class 2 were recently reported by our group, in collaboration with RFS Pharma, LLC (Tucker, GA, USA). Briefly, analog libraries of symmetric dimer compound 1, sharing a proline-valine-carbamate cap, were synthesized in three series (Figure 4). Series 1 included replacement of the two “A” phenyl rings with shorter, nonaromatic linkers, but these substitutions resulted in >1,000-fold drop in potency. However, the straight aromatic linkers could be extended by up to five rings and still retain picomolar potency. The addition of specific halogen substitution at ring “B” was able to rescue the potency of an inactive parent compound with bent linkers, which suggests a key role for conformational...
HCv NS5A inhibitors

stability related to potency. For series 2, symmetric halo-
gen substitutions (Cl, Br, I, or F) at the x and x’ positions
produced compounds with similar EC50 to the parent com-
pound. Surprisingly, an aryl substitution at the imidazole
region B maintained activity at 200 pM, and the oxaryl group
improved potency to 26 pM, suggesting an open binding
pocket in that region. In addition, an azido group substitution
of the proline-like ring “C” at position y or z did not alter
the activity (∼20 pM), while larger 1,4 triazoles were only
tolerated at position z, suggesting stereochemical restraints
of the binding pocket.

Researchers at Pharmasset Inc (now Gilead Sciences,
Foster City, CA, USA) used computational modeling to
investigate the key pharmacophore responsible for the high
activity of the class 1 dimers and theorized the importance
of an intramolecular hydrogen bond between regions B
and C to stabilize a conformation resembling a peptide
“gamma-turn.” Their development of a low picomolar
active fluorooelen-based mimetic supports that hypothesis
and may provide a structural clue about the biological site of
action. Although daclatasvir is both symmetric and dimeric
by design, newer asymmetric and monomeric analogs have
also been found to have high activity, suggesting that sym-
metry and high molecular weight dimers may not be a critical
requirement for productive interactions with NS5A, in the
next-generation compounds.

Resistance and biological space
of NS5A-directed inhibitors

Overcoming acquired resistance is a major challenge for all
antiviral targets, but for NS5A, acquired resistance defines
the target. Daclatasvir, for example, was discovered using HCV
replicon systems, which identified the rapid emergence of
key resistance-bearing mutations at residues 31 and 93 in the
NS5A coding region for genotypes 1a and 1b.

Site-directed

motagenesis at those positions resulted in significant loss
of drug activity and correlated with selection of the same
mutations in clinical trials. The genotype 1b mutations
Y93H and L31V are striking examples of aa changes that
individually increase resistance 24- and 28-fold, respectively,
but which increase resistance 14,789-fold when combined
(Table 2), suggesting a specific biological site for drug bind-
ing. The locations of these drug-resistant mutations within
the AH-D1a linker and near the D1a/D1b interface are high-
lighted for genotype 1b in Figure 1B.

The structure of aa 1–31 at the N-terminal of NS5A was
elegantly solved by NMR in lipid bilayer models. It was found
to form a flexible amphipathic α-helix between residues 5–25
that inserted along the membrane surface with hydrophobic
residues buried, polar residues exposed, and amphipathic
tryptophan residues aligned in plane (PDB ID 1R7G). The
two 3D X-ray crystal structure solutions for subdomains D1a
and D1b reveal very different dimer alignments (Figure 1).

Because the deletion of AH was required for crystallization
in each case, computational modeling has been employed to
visualize the potential drug binding region at the AH–D1a

Figure 4 Three chemical series exploring systematic substitutions of a common
compound 1 monomeric “cap” and relating specific features associated with activity
across both class 1 (dimer) and class 2 (monomer) NS5a directed inhibitors.

submit your manuscript | www.dovepress.com
Infection and Drug Resistance 2014:7
Dovepress
47
interface. Cordek et al reported the use of a full-length NS5A AH-D1 homology model (combining the α-helix from NMR with the dimer from PDB ID 3FQQ) to dock both class 1 and 2 NS5A inhibitor compounds developed at GlaxoSmithKline, PLC (Brentford, UK). While residues 28, 30, and 31 were described to be in close proximity to Tyr 93 at the dimer interface of the model, the direct binding mode was reported as “elusive.” More recently, a group from Bristol-Myers Squibb (New York, NY, USA) has proposed a symmetric binding mode at the dimer interface of their PDB ID 1ZH1-based structure; however, it does not easily explain the high activity of some class 2 compounds. A new structural review has also reported the potential for connecting AH from NMR to either of the X-ray crystal structures, but with ambiguity of the drug-binding detail. Our group has studied both dimer forms as platforms for building full-length NS5A AH–D-I homology models and tested multiple possible AH–D1a linker conformations related to drug binding. We found the PDB ID 1ZH1 dimer template to provide better AH alignments, based on chemical genetics-derived distance constraints (J Nettles, unpublished data, 2013). Our analysis for docking NS5A inhibitors to both genotype 1a and 1b models predicts the asymmetric drug binding of one cap between the pair of Tyr 93 residues at the N-terminal AH/dimer/membrane interface, with a secondary cap interaction between 93 and 31 of the two monomers (Figure 5A). This binding mode can accommodate both class 1 and class 2 binding (J Nettles, unpublished data, 2013). These results further suggest a potential for conformational changes in the AH linker region that allows higher affinity asymmetric binding of the class 1 dimers to a membrane morphology associated with LDs (Figure 5B). The “open” 93/31 site allows the second cap to penetrate closer to the D1a core packing near residue 30, consistent with the resistance data of Table 2 and the LD sequestering mechanism.

### Table 2 Resistance profile and fitness of daclatasvir, in genotype 1a and 1b replicon systems

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Amino acid substitutions</th>
<th>Replication fitness (%)</th>
<th>Potency EC&lt;sub&gt;50&lt;/sub&gt; (ng/mL), average ± SD</th>
<th>FR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 1a</td>
<td>WT</td>
<td>100</td>
<td>0.0044±0.0028</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>M28A</td>
<td>27±25</td>
<td>20.2±13.3</td>
<td>4281</td>
</tr>
<tr>
<td></td>
<td>M28T</td>
<td>31±23</td>
<td>3.0±0.3</td>
<td>682</td>
</tr>
<tr>
<td></td>
<td>M28V</td>
<td>16±11</td>
<td>0.0055±0.0019</td>
<td>1.3</td>
</tr>
<tr>
<td></td>
<td>Q30E</td>
<td>130±56</td>
<td>110.9±66.0</td>
<td>25,205</td>
</tr>
<tr>
<td></td>
<td>Q30H</td>
<td>75±31</td>
<td>6.5±1.4</td>
<td>1.477</td>
</tr>
<tr>
<td></td>
<td>Q30R</td>
<td>41±16</td>
<td>5.4±1.8</td>
<td>1.227</td>
</tr>
<tr>
<td></td>
<td>Q30K</td>
<td>19±9</td>
<td>108±52</td>
<td>24,545</td>
</tr>
<tr>
<td></td>
<td>L31M</td>
<td>55±15</td>
<td>1.5±0.5</td>
<td>341</td>
</tr>
<tr>
<td></td>
<td>L31V</td>
<td>117±29</td>
<td>14.9±4.4</td>
<td>3,386</td>
</tr>
<tr>
<td></td>
<td>H58D</td>
<td>92±9</td>
<td>2.2±0.3</td>
<td>500</td>
</tr>
<tr>
<td></td>
<td>H58P</td>
<td>266±261</td>
<td>0.0053±0.0006</td>
<td>1.2</td>
</tr>
<tr>
<td></td>
<td>Y93C</td>
<td>11±7</td>
<td>8.2±3.0</td>
<td>1,864</td>
</tr>
<tr>
<td></td>
<td>Y93H</td>
<td>18±11</td>
<td>23.9±7.0</td>
<td>5,432</td>
</tr>
<tr>
<td></td>
<td>Y93N</td>
<td>13±8</td>
<td>208.9±47.9</td>
<td>47,477</td>
</tr>
<tr>
<td></td>
<td>M28V + Q30R</td>
<td>147±55</td>
<td>1.4±0.13</td>
<td>350</td>
</tr>
<tr>
<td></td>
<td>Q30H + Y93H</td>
<td>20±6</td>
<td>409.8±153.6</td>
<td>93,136</td>
</tr>
<tr>
<td></td>
<td>Q30R + H58D</td>
<td>60±12</td>
<td>1,867±46</td>
<td>424,318</td>
</tr>
<tr>
<td>Genotype 1b</td>
<td>WT</td>
<td>100</td>
<td>0.0019±0.0007</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>L31M</td>
<td>99±23</td>
<td>0.0062±0.0014</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>L31V</td>
<td>158±54</td>
<td>0.053±0.015</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>Q54H</td>
<td>83±18</td>
<td>0.002±0.0003</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Q54N</td>
<td>83±29</td>
<td>0.002±0.0006</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Y93H</td>
<td>27±16</td>
<td>0.046±0.018</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>L31M + Y93H</td>
<td>70±68</td>
<td>13.5±12.2</td>
<td>7,105</td>
</tr>
<tr>
<td></td>
<td>L31V + Y93H</td>
<td>50±38</td>
<td>28.1±24.7</td>
<td>14,789</td>
</tr>
<tr>
<td></td>
<td>Q54H + Y93H</td>
<td>22±7</td>
<td>0.018±0.005</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>L31V + Q54H + Y93H</td>
<td>189±25</td>
<td>36.1±7.7</td>
<td>19,000</td>
</tr>
</tbody>
</table>

**Abbreviations:** EC<sub>50</sub>, 50% effective concentration; FR, fold resistance; SD, standard deviation.
suggested by Targett-Adams et al.\textsuperscript{78} Also consistent with the Targett-Adams results, the AH conformation associated with the replication complex does not support binding at either the 93/93 or 93/31 interfaces, due to a modified shape at the membrane interface (Figure 5C). Of note, these models of binding (Figure 5B) coincide with the BMS results reported by O’Boyle et al that a photoactive analog of daclatasvir was found to covalently bind a NS5A peptide spanning aa 21–30.\textsuperscript{78} 

**NS5A inhibitors in clinical trials**

According to \textsuperscript{[1]}
http://www.clinicaltrials.gov, at least 13 potent NS5A DAAs have been evaluated in clinical trials (see Table 3). Among them, three drugs are currently in Phase III clinical trials, including daclatasvir, ledipasvir, and ABT-267; seven drugs are in Phase II, and three drugs are in Phase I. To date, only three structures have been released and are summarized in Figure 3.

**Drugs currently in Phase III clinical trials**

**Daclatasvir/BMS-790052**

Daclatasvir/BMS-790052 (Bristol-Myers Squibb) is the first-in-class NS5A inhibitor of the HCV replication complex, which in humans, has demonstrated a rapid and robust HCV RNA decline (3.6 log\textsubscript{10}), with no signs of adverse effects.\textsuperscript{99} This compound blocks NS5A hyperphosphorylation and has the potential of shifting the subcellular localization of the viral protein.\textsuperscript{78,79} Daclatasvir has been shown to be highly effective against genotypes 1 and 2, and when in combination with IFN plus RBV, daclatasvir demonstrated a 100% SVR at 12 weeks posttreatment in persons infected with genotype 4. Impressively, in a Phase II study using IFN-free regimens with or without RBV, daclatasvir plus sofosbuvir (GS-7977) demonstrated a 100% SVR at 4 weeks (SVR4) and a 100% SVR12 in genotype 1–infected subjects who were either treatment naïve or who had failed prior treatment with telaprevir or boceprevir plus PEG-IFN/RBV, and 91% for genotypes 2– and 3–infected persons.\textsuperscript{100} Furthermore, when combined with NS3PI, this was the first compound to demonstrate the proof of concept that an IFN-free regimen could eradicate HCV.\textsuperscript{101} Based on the Phase II study results, which look promising, Phase III studies of the use of daclatasvir in combination with asunaprevir in genotype 1b treatment-naïve individuals are currently ongoing, and studies of the combination with asunaprevir and BMS-791325 are planned to start shortly.\textsuperscript{102}
Table 3 NS5A agents in clinical development for chronic HCV infection

<table>
<thead>
<tr>
<th>Drug name (company)</th>
<th>Phase</th>
<th>In vitro activity EC_{50} (pm)</th>
<th>Genotype specificity</th>
<th>Development of resistance</th>
<th>Drug combination Phase I, IIa, IIb, or III</th>
<th>Adverse-effect profile</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daclatasvir/ BMS-790052 (Bristol-Myers Squibb)</td>
<td>III</td>
<td>9–50</td>
<td>1b &gt; 2a &gt; 1a</td>
<td>Low/intermediate</td>
<td>Y95H and L31M</td>
<td>Dual or triple with DAAs</td>
</tr>
<tr>
<td>Ledipasvir/GS-5885 (Gilead)</td>
<td>III</td>
<td>4–2.1 × 10^3</td>
<td>1b &gt; 4a, 6a &gt; 2a, 3a</td>
<td>30 and 31 in GT1a and 93 in GT1b</td>
<td>Low/intermediate</td>
<td>Dual or triple or quadruple with DAAs/+, RBV, SVR8/12 (87%–98%)</td>
</tr>
<tr>
<td>ACH-3102 (Achillion)</td>
<td>II</td>
<td>4–10</td>
<td>1–5</td>
<td>Low</td>
<td>Y93H</td>
<td>Single dose: HCV RNA levels declined &gt;3.7 log_{10} in GT1a.</td>
</tr>
<tr>
<td>IDX-719 (Idenix)</td>
<td>II</td>
<td>2–24</td>
<td>1–5</td>
<td>Y93H</td>
<td>3-day monotherapy: HCV levels declined &gt;3 log_{10} for GT1–4.</td>
<td>No significant adverse effects</td>
</tr>
<tr>
<td>MK-8742 (Merck)</td>
<td>II</td>
<td>1a/1b, 2a, 3a, and 4a: 3–20</td>
<td>1–4</td>
<td>Low</td>
<td>Phase I – unavailable</td>
<td>Phase II: + RBV + MK-5172 (PI)</td>
</tr>
<tr>
<td>AZD-7295/A-831 (AstraZeneca/Arrow)</td>
<td>II</td>
<td>1b: 7 × 10^3</td>
<td>1a: 1.2 × 10^4</td>
<td>Unavailable</td>
<td>Unavailable</td>
<td>Unavailable</td>
</tr>
<tr>
<td>GS2336805 (GlaxoSmithKline)</td>
<td>II</td>
<td>1.8–44</td>
<td>4a, 5a &gt; 1b, 6ab &gt; 1a &gt; 2a, 3a, 6c–g, 6h–n</td>
<td>Unavailable</td>
<td>+ VX-135 ± RBV</td>
<td>Mild headache</td>
</tr>
<tr>
<td>PPI-668 (Presidio)</td>
<td>II</td>
<td>20–1.3 × 10^3</td>
<td>1–7</td>
<td>Unavailable</td>
<td>+ BI201335 (faldaprevir) and BI207127 ± RBV</td>
<td>None</td>
</tr>
<tr>
<td>GS-5816 (Gilead)</td>
<td>II</td>
<td>7–59</td>
<td>1–6</td>
<td>Unavailable</td>
<td>+ Sofosbuvir (GS-7977)</td>
<td>None</td>
</tr>
<tr>
<td>EDP-239 (Novartis)</td>
<td>I</td>
<td>4–34</td>
<td>1b &gt; 1a</td>
<td>Unavailable</td>
<td>Currently undergoing Phase I</td>
<td>Unavailable</td>
</tr>
<tr>
<td>ACH-2928 (Achillion)</td>
<td>I</td>
<td>2–46</td>
<td>1 &gt; 2–6</td>
<td>Intermediate</td>
<td>3-day monotherapy</td>
<td>Anemia, fatigue, flu-like symptoms, depression</td>
</tr>
<tr>
<td>PPI-461 (Presidio)</td>
<td>I</td>
<td>Unavailable</td>
<td>1–6</td>
<td>28, 30, 31, and 93</td>
<td>NA</td>
<td>None</td>
</tr>
</tbody>
</table>

Notes: Bristol-Myers Squibb (New York, NY, USA); Gilead (Foster City, CA, USA); AbbVie (North Chicago, IL, USA); Achillion Pharmaceuticals (New Haven, CT, USA); Idenix Pharmaceuticals, Inc (Cambridge, MA, USA); Merck and Co, Inc (Whitehouse Station, NJ, USA); AstraZeneca (London, UK); Arrow Therapeutics Limited (London, UK); GlaxoSmithKline, PLC (Brentford, UK); Presidio Pharmaceuticals, Inc (San Francisco, CA, USA); Novartis Pharmaceuticals Corp (Basel, Switzerland).

Abbreviations: DAAs, direct-acting antiviral agent; EC_{50}, median effective concentration; GT, genotype(s); HCV, hepatitis C virus; NA, not available; NS5A, nonstructural protein 5A; PEG, peginterferon; PI, protease inhibitor; RBV, ribavirin; RNA, ribonucleic acid; SVR4/12/24, sustained virologic response at week 4, 12, and 24 posttreatment; SVRB/12, sustained virologic response at week 8 and 12 posttreatment.

Table 4 DAA activity in HCV-infected human and animal models

<table>
<thead>
<tr>
<th>Drug name (company)</th>
<th>IC_{50} (pm)</th>
<th>Replication-competent constructs</th>
<th>Genotype(s) screened</th>
<th>Genotype(s) of resistance developed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daclatasvir/BMS-790052 (Bristol-Myers Squibb)</td>
<td>9–50</td>
<td>Y93H</td>
<td>GT1, 2, 3, 4</td>
<td>GT1b, 2a, 3a, 4a</td>
</tr>
<tr>
<td>Ledipasvir/GS-5885 (Gilead)</td>
<td>4–2.1 × 10^3</td>
<td>GT1, 2, 3, 4</td>
<td>GT1b, 2a, 3a, 4a</td>
<td>GT1b, 2a, 3a, 4a</td>
</tr>
<tr>
<td>ACH-3102 (Achillion)</td>
<td>4–10</td>
<td>GT1, 2, 3, 4</td>
<td>GT1b, 2a, 3a, 4a</td>
<td>GT1b, 2a, 3a, 4a</td>
</tr>
<tr>
<td>IDX-719 (Idenix)</td>
<td>2–24</td>
<td>GT1, 2, 3, 4</td>
<td>GT1b, 2a, 3a, 4a</td>
<td>GT1b, 2a, 3a, 4a</td>
</tr>
<tr>
<td>MK-8742 (Merck)</td>
<td>1a/1b, 2a, 3a, and 4a: 3–20</td>
<td>GT1, 2, 3, 4</td>
<td>GT1b, 2a, 3a, 4a</td>
<td>GT1b, 2a, 3a, 4a</td>
</tr>
<tr>
<td>AZD-7295/A-831 (AstraZeneca/Arrow)</td>
<td>1b: 7 × 10^3</td>
<td>GT1, 2, 3, 4</td>
<td>GT1b, 2a, 3a, 4a</td>
<td>GT1b, 2a, 3a, 4a</td>
</tr>
<tr>
<td>GS2336805 (GlaxoSmithKline)</td>
<td>1.8–44</td>
<td>GT1, 2, 3, 4</td>
<td>GT1b, 2a, 3a, 4a</td>
<td>GT1b, 2a, 3a, 4a</td>
</tr>
<tr>
<td>PPI-668 (Presidio)</td>
<td>20–1.3 × 10^3</td>
<td>GT1, 2, 3, 4</td>
<td>GT1b, 2a, 3a, 4a</td>
<td>GT1b, 2a, 3a, 4a</td>
</tr>
<tr>
<td>GS-5816 (Gilead)</td>
<td>7–59</td>
<td>GT1, 2, 3, 4</td>
<td>GT1b, 2a, 3a, 4a</td>
<td>GT1b, 2a, 3a, 4a</td>
</tr>
<tr>
<td>EDP-239 (Novartis)</td>
<td>4–34</td>
<td>GT1, 2, 3, 4</td>
<td>GT1b, 2a, 3a, 4a</td>
<td>GT1b, 2a, 3a, 4a</td>
</tr>
<tr>
<td>ACH-2928 (Achillion)</td>
<td>2–46</td>
<td>GT1, 2, 3, 4</td>
<td>GT1b, 2a, 3a, 4a</td>
<td>GT1b, 2a, 3a, 4a</td>
</tr>
<tr>
<td>PPI-461 (Presidio)</td>
<td>Unavailable</td>
<td>GT1, 2, 3, 4</td>
<td>GT1b, 2a, 3a, 4a</td>
<td>GT1b, 2a, 3a, 4a</td>
</tr>
</tbody>
</table>

Notes: Bristol-Myers Squibb (New York, NY, USA); Gilead (Foster City, CA, USA); AbbVie (North Chicago, IL, USA); Achillion Pharmaceuticals (New Haven, CT, USA); Idenix Pharmaceuticals, Inc (Cambridge, MA, USA); Merck and Co, Inc (Whitehouse Station, NJ, USA); AstraZeneca (London, UK); Arrow Therapeutics Limited (London, UK); GlaxoSmithKline, PLC (Brentford, UK); Presidio Pharmaceuticals, Inc (San Francisco, CA, USA); Novartis Pharmaceuticals Corp (Basel, Switzerland).

Abbreviations: IC_{50}, half-maximal inhibitory concentration; IC_{50}, half-maximal inhibitory concentration; DAA, direct-acting antiviral agent; ECF_{50}, median effective concentration; GT, genotype(s); HCV, hepatitis C virus; NA, not available; NS5A, nonstructural protein 5A; PEG, peginterferon; PI, protease inhibitor; RBV, ribavirin; RNA, ribonucleic acid; SVR4/12/24, sustained virologic response at week 4, 12, and 24 posttreatment; SVRB/12, sustained virologic response at week 8 and 12 posttreatment.

high SVR12 rates in treatment-naïve, IL28B CC patients, which were comparable with the results of 24 weeks treatment with PEG-IFN plus RBV. The four-drug therapy (ledipasvir plus GS-9451 plus PEG-IFN plus RBV) was generally safe and well tolerated; however, treatment was discontinued due to a severe pancytopenia case. In October 2012, Gilead initiated a combination study called ION-1 in a treatment-naïve genotype 1 HCV-infected population, with fixed doses (QD) for 12 or 24 weeks of ledipasvir and sofosbuvir, with and without RBV, which led to SVR4 >60%, with no significant safety issues. A second follow-up study (ION-2) was initiated (January 2013) involving treatment of nonresponders infected with the HCV genotype 1, with fixed doses (QD) of ledipasvir and sofosbuvir, with RBV (12 weeks) or without RBV (24 weeks). A third Phase III trial was initiated in May, 2013 (ION-3) comparing 8 weeks duration with 12 weeks duration, with fixed doses (QD) of ledipasvir and sofosbuvir with and without RBV, in 600 noncirrhotic, treatment-naïve HCV genotype 1–infected subjects.

ABT-267

A Phase III clinical trial involving the combination of three DAAs plus a protease booster and RBV is currently underway. In a Phase IIb clinical trial with a quintuple twice-a-day drug combination of ABT-267 (AbbVie, North Chicago, IL, USA) plus the PI ABT-450 plus ritonavir plus the nonnucleoside inhibitor ABT-333 plus RBV, a SVR12 of 98% and 93% was achieved in treatment-naïve persons and null responders infected with HCV genotype 1, respectively (Table 3).

Infection and Drug Resistance 2014:7
Drugs currently in Phase II clinical trials

ACH-3102
ACH-3102 (Achillion Pharmaceuticals) is a potent second-generation NS5A inhibitor with a demonstrated high pharmacologic barrier to resistance and a low potential for the emergence of resistant variants in genotype 1 replicon systems. In a Phase Ia clinical trial, ACH-3102 demonstrated a rapid and robust HCV RNA decline (3.6–4.6 log_{10} range) in genotype 1–infected subjects. A Phase II clinical trial of ACH-3102 with RBV has been initiated (Table 3).

Samatasvir (IDX719)
Samatasvir (Idenix Pharmaceuticals, Inc, Cambridge, MA, USA) has been shown to be highly potent against genotypes 1–4 in vitro; however, a low-resistance barrier to the Y93H variant has been demonstrated with this NS5A inhibitor. Nevertheless, a Phase II clinical trial is planned with samatasvir plus two other DAAs (TMC647055, a nonnucleoside polymerase inhibitor; and simeprevir, a PI) from Janssen (Janssen Pharmaceuticals, Inc, Titusville, NJ, USA).

MK-8742
MK-8742 (Merck) is a highly potent compound against genotype 1. It appears to function as a disruptor of the replication complex. In combination with MK-5172 (a PI), this candidate drug exhibited a high barrier to the development of escape mutants. Phase II clinical trials are underway.

AZD-7295/A-831
AZD-7295 (AstraZeneca, London, UK; Arrow Pharmaceutical, Inc) initially demonstrated promising potency against genotypes 1b and 1a replicons (EC_{50}=7 nM and 1.24 µM, respectively). In 2008, a Phase II trial of AZD7295 was initiated. The status of this compound remains unknown.

GSK2336805
GSK2336805 (AstraZeneca/Arrow) is a highly potent NS5A inhibitor displaying low EC_{50} values (7–59 pM) against genotypes 1–6. GS-5816 has also shown a high-resistance barrier and retains potency against common NS5A polymorphisms and resistance mutations (EC_{50}=130 pM against the L31M mutation and 121 pM against the Y93C mutation). In addition, GS-5816 was shown to remain active against mutations from other classes of HCV inhibitors and to show additive to moderately synergistic activities when combined with other anti-HCV agents (including sofosbuvir).

Drugs currently in Phase I clinical trials

ACH-2928
ACH2928 (Achillion Pharmaceuticals, New Haven, CT, USA) is a highly potent NS5A inhibitor. In a 3-day, monotherapy Phase I clinical trial, this compound demonstrated an impressive and rapid reduction of HCV RNA levels (3.7 log_{10}) in persons infected with genotype 1.
is a potent NS5A-targeted molecule, which in vitro, has demonstrated picomolar activity against genotypes 1b ($EC_{50}=7$ pM) and 1a ($EC_{50}=31$ pM). The combination of EDP-239 with the cyclophilin inhibitor alisporivir resulted in a strong synergistic anti-HCV effect against genotypes 1–3. Novartis has recently initiated Phase I clinical trials of EDP-239.

PPI-461

PPI-461 (Presidio Pharmaceuticals, Inc), Presidio’s first-generation NS5A inhibitor has shown potent in vitro activity for the HCV genotypes 1–6 and up to a 3.6 log$_{10}$ load reduction after 3 days of monotherapy (100 and 200 mg oral doses) in HCV genotype 1–infected subjects. However, a rapid emergence of resistance was observed (at residues 28, 30, 31, and 93). Presidio’s second-generation NS5A inhibitor, PPI-668, also has pan-genotypic activity (described above).

Conclusion

Despite the current gaps in our understanding of NS5A, this NS protein has been implicated as an important modulator of critical viral functions, including viral RNA binding and replication, virus assembly, and regulation of the antiviral IFN response. Together, these roles present a unique platform for NS5A inhibitors, to be combined with more traditional target-based drug discovery. NS5A-directed compounds are considered to be the most potent anti-HCV molecules ever discovered. However, their Achilles heel is that they select drug-resistant mutants fast and to be effective, must be used with other potent DAA drugs, to prevent clinical resistance. Structure-based models have demonstrated the potential for identifying target domains and spatial interactions that rationalize the selection of resistance mutations at specific positions within NS5A and potential binding partners (eg, residues 93 and 31). Continued SAR studies will further elucidate the mechanism(s) of action of these small molecules and facilitate the discovery of new drugs with higher barrier to resistance.

NS5A-targeted therapies demonstrate a remarkable capacity to inhibit HCV RNA replication, with minimal in vivo toxicity. At least two molecules (daclatasvir and ledipasvir) are being clinically evaluated in IFN-free combination therapies. NS5A inhibitors appear to be emerging as important components of HCV DAA regimens with dual functionality. In addition to having picomolar potency, they can synergize with other DAA, targeting different viral proteins, to prevent and suppress the emergence of resistant viruses. If NS5A inhibitors can exercise their remarkable potency to rapidly drive down virus replication within the protection offered by other DAAs, then resistance to any one DAA component may be suppressed by other components in the combination regimens. Thanks to these advances, the future is looking promising for the millions of HCV-infected individuals. An IFN-free, oral, once-daily, pan-genotypic drug combination of a nucleoside analog, such as sofosbuvir, with a next-generation pan-genotypic NS5A drug, such as GS-5816, may play a pivotal role and could potentially cure millions of chronically infected HCV individuals and result in global HCV eradication in the near future.

Acknowledgments

This work was supported in part by National Institutes of Health grant 5P30-AI-50409 (Centers for AIDS Research) and by the Department of Veterans Affairs. The authors thank Judy Matthew for her careful editing of the manuscript.

Disclosure

The authors report no conflicts of interest in this work.

References


113. Gane E, Foster GR, Clanciara J, et al. Antiviral activity, pharmacokinetics, and tolerability of AZD7295, a novel NS5A inhibitor, in a placebo-controlled multiple ascending dose study in HCV genotype 1 and 3 patients. Abstract presented at the 45th Annual Meeting of the European Association for the Study of the Liver; April 14–18, 2010; Vienna, Austria.

114. Spreen W, Wilfredt D, Bechtel J, et al. GSK2336805 HCV NS5A inhibitor demonstrates potent antiviral activity in chronic hepatitis C (CHC) genotype 1 infection: Results from a first time in human (FTH) single and repeat dose study. Presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; November 6–9, 2011; San Francisco, CA.

115. Spreen W, Wilfredt D, Bechtel J, et al. GSK2336805 HCV NS5A inhibitor demonstrates potent antiviral activity in chronic hepatitis C (CHC) genotype 1 infection: Results from a first time in human (FTH) single and repeat dose study. Presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; November 6–9, 2011; San Francisco, CA.


